Abivax ADR [ABVX] stock prices are up 5.41% to $104.29 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ABVX shares have gain 15.28% over the last week, with a monthly amount glided 26.57%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abivax ADR [NASDAQ: ABVX] stock has seen the most recent analyst activity on October 13, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $142. Previously, Morgan Stanley upgraded its rating to Overweight on July 23, 2025, and kept the price target unchanged to $71. On March 20, 2025, Morgan Stanley initiated with a Equal-Weight rating and assigned a price target of $12 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $33 on December 04, 2024. Laidlaw initiated its recommendation with a Buy and recommended $48 as its price target on July 29, 2024. BTIG Research started tracking with a Buy rating for this stock on May 20, 2024, and assigned it a price target of $43. In a note dated April 29, 2024, Piper Sandler initiated an Overweight rating and provided a target price of $42 on this stock.
The stock price of Abivax ADR [ABVX] has been fluctuating between $4.77 and $98.94 over the past year. Currently, Wall Street analysts expect the stock to reach $120 within the next 12 months. Abivax ADR [NASDAQ: ABVX] shares were valued at $104.29 at the most recent close of the market. An investor can expect a potential return of 15.06% based on the average ABVX price forecast.
Analyzing the ABVX fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -33.06%, Pretax Profit Margin comes in at -33.1%, and Net Profit Margin reading is -32.44%. To continue investigating profitability, this company’s Return on Assets is posted at -1.63, Equity is 50.78 and Total Capital is -27.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 100.32 points at the first support level, and at 96.36 for the second support level. However, for the 1st resistance point, the stock is sitting at 107.49, and for the 2nd resistance point, it is at 110.70.
Ratios To Look Out For
It’s worth pointing out that Abivax ADR [NASDAQ:ABVX]’s Current Ratio is 0.77. Also, the Quick Ratio is 0.77, while the Cash Ratio stands at 0.54.
Transactions by insiders
Recent insider trading involved Sofinnova Crossover I SLP, Affiliate, that happened on Oct 28 ’25 when 1.2 million shares were purchased.
